p.101 抽出テキスト

disease. Genet Med 2011; 13: 563-568. PMID: 21415759 284. Kamdar F, Garry DJ. Dystrophin-Deficient Cardiomyopathy. J Am Coll Cardiol 2016; 67: 2533-2546. PMID: 27230049 285. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011; 124: 2181- 2184. PMID: 22083145 286. 日本循環器学会.遺伝性不整脈の診療に関するガイドライン(2017年改訂版).https://www.j-circ.or.jp/cms/wp-content/ uploads/2017/12/JCS2017_aonuma_h.pdf 287. Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation 2009; 120: 1761-1767. PMID: 19841298 288. Yoshinaga M, Ushinohama H, Sato S, et al. Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals. Circ Arrhythm Electrophysiol 2013; 6: 932-938. PMID: 24036083 289. Itoh H, Crotti L, Aiba T, et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J 2016; 37: 1456-1464. PMID: 26715165 290. Aiba T. Recent understanding of clinical sequencing and genebased risk stratification in inherited primary arrhythmia syndrome. J Cardiol 2019; 73: 335-342. PMID: 30910390 291. Wilde AAM, Semsarian C, Márquez MF, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. J Arrhythm 2022; 38: 491-553. PMID: 35936045 292. Fukuyama M, Wang Q, Kato K, et al. Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation and variant phenotypes. Europace 2014; 16: 1828-1837. PMID: 24728418 293. Makita N, Behr E, Shimizu W, et al. The E 1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008; 118: 2219- 2229. PMID: 18451998 294. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8: 1308-1339. PMID: 21787999 295. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293-296. PMID: 9521325 296. Hosseini SM, Kim R, Udupa S, et al. National Institutes of Health Clinical Genome Resource Consortium. Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome. Circulation 2018; 138: 1195-1205. PMID: 29959160 297. Wijeyeratne YD, Tanck MW, Mizusawa Y, et al. SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families. Circ Genom Precis Med 2020; 13: e002911. PMID: 33164571 298. Yamagata K, Horie M, Aiba T, et al. Genotype-Phenotype Correlation of SCN 5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry. Circulation 2017; 135: 2255-2270. PMID: 28341781 299. Ishikawa T, Kimoto H, Mishima H, et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur Heart J 2021; 42: 2854- 2863. PMID: 34219138 300. Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN 5 A-SCN 1 0 A and HEY 2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013; 45: 1044-1049. PMID: 23872634 301. Walsh R, Adler A, Amin AS, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J 2022; 43: 1500-1510. PMID: 34557911 302. Ng K, Titus EW, Lieve KV, et al. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ 2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation 2020; 142: 932-947. PMID: 32693635 303. Shimamoto K, Ohno S, Kato K, et al. Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1. Heart 2022; 108: 840-847. PMID: 35135837 304. Ohno S, Hasegawa K, Horie M. Gender Differences in the Inheritance Mode of RYR2 Mutations in Catecholaminergic Polymorphic Ventricular Tachycardia Patients. PLoS One 2015; 10: e0131517. PMID: 26114861 305. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013; 10: 1932- 1963. PMID: 24011539 306. Brugada R, Hong K, Dumaine R, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30-35. PMID: 14676148 307. Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109: 2394-2397. PMID: 15159330 308. Priori SG, Pandit SV, Rivolta I, et al. A novel form of short QT syndrome (SQT 3) is caused by a mutation in the KCNJ 2 gene. Circ Res 2005; 96: 800-807. PMID: 15761194 309. Thorsen K, Dam VS, Kjaer-Sorensen K, et al. Loss-of-activitymutation in the cardiac chloride-bicarbonate exchanger AE 3 causes short QT syndrome. Nat Commun 2017; 8: 1696. PMID: 29167417 310. Syeda F, Kirchhof P, Fabritz L. PITX2-dependent gene regulation in atrial fibrillation and rhythm control. J Physiol 2017; 595: 4019- 4026. PMID: 28217939 311. Pensa AV, Baman JR, Puckelwartz MJ, et al. Genetically based atrial fibrillation: Current considerations for diagnosis and management. J Cardiovasc Electrophysiol 2022; 33: 1944-1953. PMID: 35262243 312. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007; 448: 353-357. PMID: 17603472 313. Low SK, Takahashi A, Ebana Y, et al. Identification of six new genetic loci associated with atrial fibrillation in the Japanese population. Nat Genet 2017; 49: 953-958. PMID: 28416822 314. Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet 2018; 50: 1225- 1233. PMID: 29892015 315. Miyazawa K, Ito K, Ito M, et al. BioBank Japan Project. Crossancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk prediction. Nat Genet 2023; 55: 187-197. PMID: 36653681 316. Weng LC, Preis SR, Hulme OL, et al. Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation. Circulation 2018; 137: 1027-1038. PMID: 29129827 317. Choi SH, Jurgens SJ, Weng LC, et al. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank. Circ Res 2020; 126: 200-209. PMID: 31691645 318. Shoemaker MB, Husser D, Roselli C, et al. Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation. Circ Arrhythm Electrophysiol 2020; 13: e 007676. PMID: 32078373 319. Lazarte J, Dron JS, McIntyre AD, et al. Role of Common Genetic Variation in Lone Atrial Fibrillation. Circ Genom Precis Med 2021; 14: e003179. PMID: 33517663 320. Mars N, Koskela JT, Ripatti P, et al. FinnGen. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. Nat Med 2020; 26: 549-557. PMID: 32273609 321. Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond. Circ Res 2020; 127: 21-33. PMID: 32716721 322. Marfan AB Un cas de deformation congenitale des quatre membres, plue prononcee aux extremities, caracterisee par 1’ allongement des os avec un certain degre d’ amincissement. Bul Sco Chir Paris 1896; 13 :220-225. 323. Baer RW, Taussig HB, Oppenheimer EH. Congenital aneurymsmal dilatation of the aorta associated with arachnodactyly. Bull Johns Hopkins Hosp 1943; 72: 309-331. 324. Dietz HC, Cutting GR, Pyeritz RE, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 1991; 352: 337-339. PMID: 1852208 325. Milewicz DM, Pyeritz RE, Crawford ES, et al. Marfan syndrome: defective synthesis, secretion, and extracellular matrix formation of fibrillin by cultured dermal fibroblasts. J Clin Invest 1992; 89: 79-86. PMID: 1729284 326. Habashi JP, Judge DP, Holm TM, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312: 117-121. PMID: 16601194 327. ClinGen. Clinical Domain Working Groups: FBN1 Variant Curation Expert Panel. https://www.clinicalgenome.org/affiliation/50046 328. Putnam EA, Cho M, Zinn AB, et al. Delineation of the Marfan